Physician profile
Michael Sackman
NPI 1457387300
$5,349.24
in general payments reported to CMS, 2019-2025
23 companies · $1,398 in 2025
The $1,398 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $232 · 2021: $491 · 2022: $1,198 · 2023: $568 · 2024: $675 · 2025: $1,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,640.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $995.91 | 2019-2025 | Bexsero, Penmenvy, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $795.33 | 2021-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $783.33 | 2021-2025 | Wegovy |
| Amgen INC. | $565.20 | 2019-2024 | Repatha |
| Regeneron Healthcare Solutions, INC. | $354.31 | 2022-2023 | Dupixent |
| Tris Pharma INC | $335.10 | 2019-2025 | Quillivant, Dyanavel Xr, Quillichew Er |
| Otsuka America Pharmaceutical, INC. | $260.53 | 2023 | Nuedexta, Rexulti |
| Ironshore Pharmaceuticals INC. | $244.15 | 2019-2020 | |
| Pfizer INC. | $133.40 | 2019 | |
| Genzyme Corporation | $125.00 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.80 | 2023 | Trulance, Xifaxan |
| Agios Pharmaceuticals, INC. | $103.70 | 2025 | Pyrukynd |
| Merck Sharp & Dohme LLC | $98.25 | 2019-2022 | |
| Cranial Technologies, INC | $96.79 | 2022-2024 | Doc Band |
| Covidien Lp | $84.94 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $78.30 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $52.86 | 2024-2025 | |
| Cipher Pharmaceuticals US LLC | $34.22 | 2025 | Natroba, Spinosad |
| Biomarin Pharmaceutical INC. | $24.97 | 2024 | Voxzogo 1.2mg |
| Sanofi Pasteur INC. | $21.94 | 2024 | |
| Neos Therapeutics, Lp | $20.00 | 2019 | |
| Seqirus USA INC | $19.02 | 2024 | Fluad, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $12.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sackman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.